Last updated on March 2018

Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention


Brief description of study

The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocardial infarction, urgent target vessel revascularization or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first.

Clinical Study Identifier: NCT01522417

Contact Investigators or Research Sites near you

Start Over

Debbie Douglas, PhD

Osceola Regional Medical Center
Kissimmee, FL United States
  Connect »

Debbie Douglas, PhD

Emory University Hospital Midtown
Atlanta, GA United States
  Connect »

Debbie Douglas, PhD

Emory University Hospital
Atlanta, GA United States
  Connect »

Debbie Douglas, PhD

North Georgia Heart Center
Gainesville, GA United States
  Connect »

Hector R Picon, MD

Redmond Regional Medical Center
Rome, GA United States
  Connect »

Debbie Douglas, PhD

Archbold Medical Center
Thomasville, GA United States
  Connect »

Debbie Douglas, PhD

Lenox Hill Hospital
New York, NY United States
  Connect »

Mazen Abu-Fadel, MD

University of Oklahoma Health Sciences Center
Oklahoma City, OK United States
  Connect »

Debbie Douglas, PhD

Doylestown Hospital
Doylestown, PA United States
  Connect »

Debbie Douglas, PhD

Penn Presbyterian Medical Center
Philadelphia, PA United States
  Connect »

Brian K Jefferson, MD

Centennial Heart
Nashville, TN United States
  Connect »

Michael L Arcarese, MD

Chippenham Hospital
Richmond, VA United States
  Connect »

Debbie Douglas, PhD

Northside Hospital
Saint Petersburg, FL United States
  Connect »